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Abstract
Background: Glucose variability is one of components of the dysglycemia in diabetes and may play an important
role in development of diabetic vascular complications. The objective of this study was to assess the relationship
between glycemic variability determined by a continuous glucose monitoring (CGM) system and the presence and
severity of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM).
Methods: In 344 T2DM patients with chest pain, coronary angiography revealed CAD (coronary stenosis ≥ 50%
luminal diameter narrowing) in 252 patients and 92 patients without CAD. Gensini score was used to assess the
severity of CAD. All participants’ CGM parameters and biochemical characteristics were measured at baseline.
Results: Diabetic patients with CAD were older, and more were male and cigarette smokers compared with the
controls. Levels of the mean amplitude of glycemic excursions (MAGE) (3.7 ± 1.4 mmol/L vs. 3.2 ± 1.2 mmol/L,
p < 0.001), postprandial glucose excursion (PPGE) (3.9 ± 1.6 mmol/L vs. 3.6 ± 1.4 mmol/L, p = 0.036), serum high-
sensitive C-reactive protein (hs-CRP) (10.7 ± 12.4 mg/L vs. 5.8 ± 6.7 mg/L, p < 0.001) and creatinine (Cr) (87 ± 23
mmol/L vs. 77 ± 14 mmol/L, p < 0.001) were significantly higher in patients with CAD than in patients without
CAD. Gensini score closely correlated with age, MAGE, PPGE, hemoglobin A1c (HbA1c), hs-CRP and total cholesterol
(TC). Multivariate analysis indicated that age (p < 0.001), MAGE (p < 0.001), serum levels of HbA1c (p = 0.022) and
hs-CRP (p = 0.005) were independent determinants for Gensini score. Logistic regression analysis revealed that
MAGE ≥ 3.4 mmol/L was an independent predictor for CAD. The area under the receiver-operating characteristic
curve for MAGE (0.618, p = 0.001) was superior to that for HbA1c (0.554, p = 0.129).
Conclusions: The intraday glycemic variability is associated with the presence and severity of CAD in patients with
T2DM. Effects of glycemic excursions on vascular complications should not be neglected in diabetes.
Background
Cardiovascular diseases, including coronary artery dis-
ease (CAD), are the major causes of morbidity and car-
diovascular death in patients with type 2 diabetes
mellitus (T2DM) [1,2]. Diabetic patients usually present
various factors contributing to the risk of cardiovascular
diseases, which include hyperglycemia, fluctuation of
blood glucose, central obesity, hyperlipidemia and
hypertension and so on [2]. Glycemic disorders are
important components of these risk factors.
Interventional studies have established that cardiovas-
cular complications are mainly or partly dependent on
sustained chronic hyperglycemia [3,4]. This glycemic
disorder can be estimated as a whole from the determi-
nation of hemoglobin A1c (HbA1c) level, which inte-
grates both basal and postprandial hyperglycemia [5,6].
The incidence of cardiovascular complications has been
identified as depending on HbA1c and on fasting and/or
postprandial hyperglycemia, whether these parameters
were investigated concomitantly or separately [7,8].
However, the glycemic disorders in T2DM are not solely
limited to sustained chronic hyperglycemia but can be
extended to the glycemic variability that includes both
upward and downward acute glucose changes [9]. Some
studies have showed that fluctuations of glucose seem to
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any medium, provided the original work is properly cited.have more deleterious effects than sustained hyperglyce-
mia in the development of diabetic complications as
acute glucose swings activate the oxidative stress
[10,11]. Recent studies have indicated that glycemic
variability might play a role in the pathogenesis of ather-
osclerosis and may be an independent risk factor for
cardiovascular complications in diabetic patients
[10-13]. Therefore, in order to assess the risk of dia-
betes, it may be necessary to evaluate not only the mean
level of glycemic control, but also the extent of glucose
excursions. However, there have been no sufficient stu-
dies presented so far that specifically evaluated the rela-
tionship between glycemic variability and coronary
artery disease in diabetic patients.
In this study, we examined the parameters of glucose
profile using continuous glucose monitoring system
(CGMS) in T2DM patients with CAD, and established a
correlation between glycemic variability and the severity
of coronary artery disease assessed by coronary angio-
gram, using the Gensini score.
Methods
Study population
We studied consecutive T2DM patients with chest pain,
who underwent coronary angiography at the Depart-
ment of Cardiology, Beijing Anzhen Hospital of Capital
Medical University. The inclusion criteria were: (i) refer-
ral to coronary angiography, due to chest pain;
(ii) admission glucose < 16.7 mmol/L, and without dia-
betic ketosis or nonketotic hyperosmolar coma. Patients’
anti-hyperglycemic therapy would be maintained as
usual until CGMS monitoring completed. Otherwise,
t h ep a t i e n tw o u l db ee x c l u d e df r o mt h es t u d y .I na d d i -
tion, patients with acute coronary syndrome, infectious
diseases, previous coronary artery bypass graft surgery
and previous percutaneous coronary intervention were
not included. Thus, 344 patients with complete data
were included in the final analysis. Hypertension was
defined as systolic blood pressure ≥ 140 mmHg and/or
diastolic blood pressure ≥ 90 mmHg or treatment with
oral anti-hypertension drugs. Hyperlipidemia was diag-
nosed according to guideline of the National Cholesterol
Education Program (ATP III). T2DM was diagnosed
according to the American Diabetes Association criteria
[14]. Renal insufficiency was defined as estimated glo-
merular filtration rate (eGFR) < 60 (ml/min/1.73 m
2).
eGFR value was calculated by MDRD equation [15]. The
study was approved beforehand by the Ethics Commit-
tee of Beijing Anzhen Hospital of Capital Medical Uni-
versity and the procedures followed were in accordance
with the institutional guidelines. The study complied
with the declaration of Helsi n k ia n di n f o r m e dc o n s e n t
was obtained from all patients.
Continuous glucose monitoring
All patients were equipped with CGMS (Medtronic Mini-
Med, USA), and were monitored for 72 consecutive
hours after admission. A CGMS sensor was inserted into
the subcutaneous abdominal fat tissue, calibrated accord-
ing to the standard Medtronic MiniMed operating guide-
lines. During CGMS monitoring, patients checked their
blood glucose level with a self-monitoring of blood glu-
cose (SMBG) device (Medisafe Mini, Terumo, Japan) at
least 4 times per day. Then, they entered the SMBG data
and time of each meal into the CGMS. After monitoring
for 72 hours, the recorded data were downloaded into a
personal computer for analysis of the glucose profile and
glucose excursion parameters with MiniMed Solutions
software. Analysis was limited to the data obtained from
the intermediate 48 hours of recording to avoid bias due
to insertion and removal of the CGMS or insufficient sta-
bility of the monitoring system. Since measurable range
of glucose by CGMS was mechanically limited from 2.2
t o2 2 . 2m m o l / L ,t h ec a s es h o w i n gt h ed a t ao u to ft h i s
range was excluded from the study. After downloading
the recorded data, three indices of glycemic variability
were analyzed from the intermediate 48 hours of data
[16]: the mean amplitude of glycemic excursions
(MAGE), the mean of daily differences (MODD) and
postprandial glucose excursion (PPGE). The MAGE was
calculated by measuring the arithmetic mean of the dif-
ferences between consecutive peaks and nadirs, provided
that the differences are greater than one standard devia-
tion of the mean glucose value. The MODD was calcu-
lated as the mean of the absolute differences between
glucose values at the same time of two consecutive days.
The PPGE was obtained by calculating the post-breakfast
increments in blood glucose.
Coronary Angiography
After CGMS monitoring finished, coronary artery angio-
graphy was performed by using standard Judkins techni-
ques or a radial approach. During cardiac catheterization,
nitroglycerine was administrated routinely in all cases
suspected of having coronary spasm. Angiographic analy-
sis was carried out by two experienced interventional car-
diologists who were blinded to the study protocol.
Angiography results were divided into CAD (≥50%
obstruction in ≥1 coronary artery) group and non-CAD
group. Gensini score assesses the severity of coronary
artery disease: it grades narrowing of the lumen of the
coronary artery and scores it as 1 for 1-25% narrowing, 2
for 26-50% narrowing, 4 for 51-75%, 8 for 76-90%, 16 for
91-99% and 32 for a completely occluded artery. This
score is then multiplied by a factor according to the
importance of the coronary artery. The multiplication
factor for a left main stem (LMS) lesion is 5. It is 2.5 for
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imal circumflex artery (CX) lesions, 1.5 for a mid-LAD
lesion, and 1 for distal LAD, mid/distal CX and right cor-
onary artery lesions. The multiplication factor for any
other branch is 0.5.
Biochemical Investigations
Blood samples were collected after overnight fasting and
stored at -70°C prior to analysis. Serum creatinine, fasting
plasma glucose (FPG), high-sensitive C-reactive protein
(hs-CRP), total cholesterol(TC), low-density lipoprotein-
cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C) and triglyceride (TG) levels were measured by
automatic biochemical analyzer (Hitachi 747, Tokyo,
Japan). Serum concentration of hemoglobin A1c (HbA1c)
was determined by high-performance liquid chromato-
graphic method using automatic HbA1c analyzer (Tosoh
HLC-723G7, Japan).
Statistical Analysis
All statistical analyses were performed by using SPSS for
Windows 13.0 (SPSS Inc, Chicago, IL, USA). Data are
presented as frequencies and percentages for categorical
variables and mean ± SD for continuous variables,
unless otherwise indicated. Differences between two
groups were assessed by using the Chi-square and
unpaired t-tests. Correlation between continuous vari-
ables was determined by Pearson correlation coeffi-
cients. Binary logistic regression analysis was performed
to identify the relative risk of the glycemic variability for
t h ep r e s e n c eo fC A D ,e x p r e s s e da so d d sr a t i o s( O R )
with 95% confidence intervals (CI). The predictive values
of MAGE and HbA1c for the presence of CAD were cal-
culated by constructing receiver-operating characteristic
(ROC) curves. To ascertain the independent contribu-
tion to severity of CAD, multivariate stepwise linear
regression analysis was made with Gensini score as the
dependent variable control for FPG, duration of dia-
betes, blood pressure, age, MAGE, MODD, PPGE,
HbA1c,B M I ,h s - C R Pa n dT C .Av a l u eo fp<0 . 0 5w a s
considered statistically significant.
Results
Clinical Characteristics
Among the 344 participants, 252 patients had angiogra-
phically-proven CAD and 92 had almost normal coron-
ary arteries (Non-CAD group). Baseline characteristics
of the two groups are shown in Table 1. The Gensini
score ranged from 0 to 162 with a mean of 67.8 ± 34.1,
as shown in Figure 1. Diabetic patients with CAD were
older, and more were male and cigarette smokers com-
pared with the patients without CAD. The CAD group
had significantly higher levels of hs-CRP and lower
levels of eGFR, but no significant differences in blood
pressure, hyperlipidemia, BMI, TC, HDL-C, LDL-C and
TG levels. In addition, most of the diabetic patients in
the CAD group and Non-CAD group were receiving
statin medication (69.4% vs. 61.9%, p > 0.05), and did
not differ significantly with the use of insulin (40.9% vs.
35.1%, p > 0.05). There was no difference in treatment
with other antidiabetic agents in diabetic patients with
and without CAD.
Glycemic variability, HbA1c and Fasting Plasma Glucose
Levels
MAGE and PPGE were significantly higher in patients
with CAD than in patients without CAD, but MODD did
not significantly differ. CAD patients had longer duration
Table 1 Baseline characteristics of diabetic patients with
(CAD) and without (Non-CAD) coronary artery disease, as
defined by coronary angiography
Non-CAD
group
(n = 92)
CAD
group
(n = 252)
p value
Male (%) 48 (52.2) 165 (65.5) 0.025
Age (years) 61 ± 9 65 ± 9 <0.001
Cigarette smoking (%) 19 (20.7) 91 (36.1) 0.007
Hypertension (%) 56 (60.9) 177 (70.2) NS
Blood pressure
Systolic (mmHg) 123 ± 17 126 ± 20 NS
Diastolic (mmHg) 76 ± 8 78 ± 9 NS
Hyperlipidemia (%) 48 (52.2) 154 (61.1) NS
Duration of diabetes (months) 58 ± 68 78 ± 77 0.022
Oral anti-hyperglycemic
therapy (%)
42 (45.7) 111 (44.0) NS
Insulin (%) 33 (35.9) 103 (40.9) NS
Statins (%) 57 (61.9) 175 (69.4) NS
Cholesterol
Total cholesterol (mmol/L) 4.6 ± 1.1 4.8 ± 1.2 NS
LDL-C (mmol/L) 2.7 ± 0.8 2.9 ± 1.0 NS
HDL-C (mmol/L) 1.0 ± 0.2 1.1 ± 0.3 NS
Triglycerides (mmol/L) 2.1 ± 1.2 2.2 ± 1.6 NS
Creatinine (μmol/L) 77 ± 19 87 ± 23 <0.001
eGFR (ml/min/1.73 m
2) 87 ± 23 79 ± 18 <0.001
Fasting plasma glucose (mmol/L) 7.3 ± 1.8 7.6 ± 2.4 NS
Hemoglobin A1c (%) 7.5 ± 1.4 7.6 ± 1.5 NS
MAGE (mmol/L) 3.2 ± 1.2 3.7 ± 1.4 <0.001
MODD (mmol/L) 2.4 ± 1.0 2.5 ± 1.0 NS
PPGE (mmol/L) 3.6 ± 1.4 3.9 ± 1.6 0.036
BMI (kg/m
2) 26.0 ± 2.2 26.4 ± 2.4 NS
hs-CRP (mg/L) 5.8 ± 6.7 10.7 ±
12.4
<0.001
Abbreviations: CAD, coronary artery disease; LDL-C, lower-density lipoprotein-
cholesterol; HDL-C, high-density lipoprotein-cholesterol; eGFR, estimated
glomerular filtration rate; MAGE, the mean amplitude of glycemic excursions;
MODD, the mean of daily differences; PPGE, postprandial blood glucose
excursions; BMI, body mass index; hs-CRP, highsensitive-C reactive protein.
Data are mean ± SD and number (%).
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HbA1c and FPG levels between two groups (Table 1).
Relationship between Gensini Score and Glycemic
variability, Age and Biochemical Parameters
Pearson correlation analysis showed that Gensini score
was closely related to MAGE(r = 0.277, p < 0.001), age
(r = 0.288, p < 0.001), PPGE (r = 0.167, p = 0.002) and
the level of HbA1c (r = 0.136, p = 0.011) (Figure 2), and
correlated significantly with the levels of hs-CRP (r =
0.132, p = 0.014) and TC (r = 0.108, p = 0.045), but not
with MODD, eGFR, duration of diabetes, blood pressure
and other factors. In the final multivariate linear regres-
sion analysis model that explained 19.1% (adjusted mul-
tiple R
2 = 0.191) of the variation in Gensini score, the
independent determinants were age (p < 0.001), MAGE
(p < 0.001), hs-CRP (p = 0.002) and HbA1c (p = 0.022)
(Table 2).
Logistic Regression Analysis for Independent
Determinants of CAD
Cigarette smoking, male, older age (≥65 years), high MAGE
level (≥3.4 mmol/L) and high hs-CRP level (> 5 mg/L) were
found to be independent risk factors for the presence of
CAD in T2DM patients, having OR 2.492 (p = 0.005), 1.936
(p = 0.036), 2.516 (p = 0.002), 2.612 (p = 0.002), and 2.851
(p = 0.009), respectively (Figure 3).
ROC Curve for MAGE and HbA1c in Predicting CAD in
T2DM
The area under the ROC curve for MAGE (0.618, 95%
CI 0.555 to 0.680, p = 0.001) was superior to that
for HbA1c (0.554, 95%CI 0.487 to 0.620, p = 0.129)
(Figure 4).
Discussion
Blood glucose level continuously fluctuates within a cer-
tain range in the human body. In diabetic patients, gly-
cemic disorders include both sustained chronic
hyperglycemia and glucose excursions. Patients with
similar mean glucose or HbA1c levels can have markedly
different glycemic excursions. Our study shows levels of
FPG and HbA1c were not higher in CAD group patients
than in the controls (p > 0.05). According to the tradi-
tional view, the two groups should have similar blood
glucose control. However, we found that MAGE and
PPGE levels in T2DM patients with CAD were higher
than in T2DM patients without CAD. This result
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Figure 1 Distribution of Gensini score among participants.
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Page 4 of 9indicates that glucose excursions can not be neglected as
an important aspect of glucose disorders and suggests it
may be associated with coronary artery disease in
T2DM patients.
Although the influence of glucose control, as assessed
primarily by HbA1c levels, on the development of dia-
betes complications has been proven in numerous
large-scale epidemiological studies [3,7,17], there is still
an extensive debate about glucose variability as a risk
factor for complications independent of HbA1c in dia-
betes[18,19]. A retrospective analysis from the Diabetes
Control Complications Trial (DCCT) showed that
HbA1c, as well as blood glucose fluctuation, seem to be
associated with the microvascular complications of
type1 diabetes [20]. A single study in T2DM demon-
strated that fasting plasma glucose variability is a pre-
dictor of the onset of retinopathy in patients [21].
However, the controversial results were concluded from
Kilpatrick et al. They independently performed analysis
of the data of the DCCT showing that blood glucose
variability was not related to the development or pro-
gression of either retinopathy or nephropathy in type1
diabetes [22]. Thirteen years later, the DCCT statisti-
cians themselves corrected their previous findings and
refuted the relation of glucose fluctuation and microvas-
cular complications [23]. However, the DCCT was not
designed to determine the impact of glycemic variability
on the risk of the vascular complications of diabetes,
and in fact the investigators required two attempts to
report an acceptable statistical model. Since this was a
post hoc analysis, at best it is hypothesis-generating.
In fact, more and more evidences have been found
that glycemic variability may be an important parameter
used to resolve potential clinical problems in diabetic
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Figure 2 Simple linear correlation of Gensini score and age, MAGE, PPGE and hemoglobin A1c in patients with type 2 diabetes.
Su et al. Cardiovascular Diabetology 2011, 10:19
http://www.cardiab.com/content/10/1/19
Page 5 of 9patients [24]. Some researchers identified several impor-
tant associations between postchallenge glucose excur-
sions and known risk factors for atherosclerosis, and
suggested that postchallenge glucose excursion is inde-
pendently related to carotid intima-media thickness and
may contribute to the development of atherosclerosis
in individuals with T2DM independent of other risk
factors [12,13]. The Verona Diabetes study reported that
long-term variability of fasting glucose is an independent
predictor of mortality in T2DM patients [25]. Some stu-
dies concluded that glucose variability was a significant
predictor of mortality in critically ill patients indepen-
dently from mean glucose level and severity of illness
[26-28]. In the present study, MAGE≥3.4 mmol/L was
found to be an independent predictor for the presence
of CAD (OR 2.612; p = 0.002). Furthermore, the ROC
plot also demonstrated that the MAGE level was a sig-
nificant predictor for the presence of CAD (p = 0.001),
whereas HbA1c was not (p = 0.129). These results indi-
cate that intraday glucose excursion might contribute to
generation of atherosclerosis even more specifically than
sustained chronic hyperglycemia.
At present, the identified role of glucose variability in
pathogenesis of atherosclerosis is not clear. Hyperglyce-
mia is thought to induce oxidative stress and interfere
with normal endothelial function by overproduction of
reactive oxygen species, which results in atherosclerosis
through several molecular mechanisms. In addition, glu-
cose variability might contribute to these processes as
Table 2 Multivariate analysis of determinants of Gensini
score
Independent
variables
Unstandardized
coefficients
Standardized
coefficients b
t p value
BS E
Constant -55.587 14.441 -3.849 0
Age 1.004 0.181 0.270 5.533 0.000
MAGE 7.010 1.466 0.237 4.783 0.000
hs-CRP 0.468 0.148 0.159 3.164 0.002
HbA 1c 2.641 1.145 0.114 2.306 0.022
Adjusted
multiple R
2
0.191 0
Abbreviations: MAGE, the mean amplitude of glycemic excursions; hs-CRP,
highsensitive-C reactive protein; HbA1c, Hemoglobin A1c.
Figure 3 Multivariate analysis for independent determinants of coronary artery disease (CAD). Smoking, male, older age, MAGE and
hs-CRP were independent risk factors for CAD.
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Page 6 of 9well. Recent in vitro studies indicate that glucose fluc-
tuations can activate nuclear factor-Ba n dp r o t e i n
kinase C (PKC) pathway, leading to a greater expression
of the adhesion molecules and excess formation of
advanced glycation end-products than stable high glu-
cose [29,30]. Some studies reported that intermittent
hyperglycemia induced a higher degree of apoptosis in
endothelial cells than chronic hyperglycemia [10,31].
Quagliaro et al. showed that the apoptosis of endothelial
cells exposed to intermittent high glucose may be
related to a reactive oxygen species (ROS) overproduc-
tion, through PKC-dependent activation of nicotinamide
adenine dinucleotide phosphate (NADPH)-oxidase [30].
NADPH oxidase is a major cause of atherosclerosis.
That suggests blood glucose excursion plays an impor-
tant role in the occurrence and acceleration of athero-
sclerosis in diabetes. However, the relationship between
glycemic variability and oxidative stress was not consis-
tently reproduced in human studies [11,32]. These dis-
crepant findings might be explained by differences in
duration and frequency of the periods with alternating
glycemia as well as differences in methods used for
oxidative stress quantification. Furthermore, severe gly-
cemic disorders may adversely affect circadian variation
of cardiac autonomic modulation and circadian blood
pressure variability which are associated with mortality
and morbidity of cardiovascular disease [33,34]. Takei
et al. find acute hyperglycemia may induce sympathetic
dysfunction through multiple mechanisms, including
hyperglycemia, hyperinsulinemia, and increased oxida-
tive stress, whereas coronary microvascular dysfunction
is closely related to sympathetic activation [35].
In our study, Pearson correlation analysis showed that
Gensini score correlated positively with the level of
MAGE(r = 0.277, p < 0.001), PPGE (r = 0.167, p =
0.002) and HbA1c(r = 0.136, p = 0.011), indicating a
pronounced proatherogenic effect of worse glycemic dis-
orders, which is consistent with previous findings.
Furthermore, multivariate regression analysis revealed
that MAGE and HbA1c were independent risk factors
for the severity of CAD. These results indicate that
intraday glucose excursion is an important contributing
factor in the severity of coronary artery disease, which is
independent of the average level of blood glucose.
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ing mainly on HbA1c within a target range is inadequate
for timely therapeutic adjustments and reducing the risk
of coronary artery disease. To accomplish this goal, the
CGMS appears to be a very useful tool in primary care
and its use should be expanded for effective manage-
ment of T2DM.
A few limitations of this study should be recognized.
Firstly, the sample size was relatively small in this study,
so that some subgroup comparisons may have lacked
power to detect significant differences for selected vari-
ables. Secondly, although we had maintained the patients’
anti-hyperglycemic therapy as usual and avoided glucose
infusion during CGMS monitoring period, some factors,
such as different diets, physical and emotional stress etc.,
which may affect levels of admission glucose fluctuations
couldn’t be all prevented. Thirdly, lack of microvascular
complications data, we didn’t include those risk factors in
study. Fourthly, due to the fact that the present study
was a cross-sectional design, our results only show the
association between glycemic variability and prevalent
CAD rather than incident CAD. All subjects in the pre-
sent study were scheduled for coronary angiography for
their suffering chest pain in cardiovascular department of
Beijing Anzhen hospital. Therefore, it is likely that
enrolled T2DM patients had greater risk for CAD than
ordinary T2DM patients.
Conclusions
The present study shows that the intraday glycemic
variability is associated with the presence and severity of
CAD in patients with T2DM. Recent accumulated evi-
dence suggested that blood glucose excursions may play
an important role in the occurrence and development of
atherosclerosis in diabetes. There should be an emphasis
on efforts to control all aspects of blood glucose disor-
ders including HbA1c, FPG, postprandial glucose, as well
as glucose fluctuations. Further well-designed studies
are warranted to examine if reduction of glucose excur-
sions has a substantial impact on CAD development in
patients with T2DM.
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